文献速递白血病

优化儿童B细胞急性淋巴细胞白血病风险分层:联合IKZF1plus与第15天MRD阳性

Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity.
PubMed 文献 · Br J Haematol · 2024-03-13

本研究在MRD指导的TPOG-ALL-2013方案中纳入412例1-18岁初诊B-ALL患者,评估IKZF1状态联合MRD的预后影响。IKZF1缺失(14.6%)与IKZF1plus(7.8%)均独立预测较差结局;IKZF1plus在费城染色体阴性ALL中占4.1%,5年无事件生存率53.9%,显著低于单纯IKZF1缺失的83.8%和野生型IKZF1的91.3%(p<0.0001)。

要点

  • IKZF1缺失(14.6%)与IKZF1plus(7.8%)均独立预测儿童B-ALL较差结局。
  • IKZF1plus在费城染色体阴性ALL中占4.1%,5年无事件生存率53.9%。
  • 第15天MRD≥0.01%且IKZF1plus的暂定高危患者无事件生存率42.0%。

核心结论

  • IKZF1plus与第15天MRD阳性联合可识别费城染色体阴性B-ALL中复发风险约50%的亚组。
  • 作者认为评估IKZF1plus联合第15天MRD阳性有助于识别不良结局风险增加的患者,可能减少过度治疗。

研究设计与样本

  • 在MRD指导的TPOG-ALL-2013方案中评估IKZF1状态联合MRD的预后影响,纳入412例1-18岁初诊B-ALL患者。
  • 采用多重连接依赖探针扩增确定IKZF1状态。
  • IKZF1缺失合并CDKN2A、CDKN2B、PAX5或PAR1区域缺失且无ERG缺失定义为IKZF1plus。

主要发现

  • IKZF1缺失占14.6%,IKZF1plus占7.8%,两者均独立预测B-ALL较差结局。
  • IKZF1plus在费城染色体阴性ALL中占4.1%,5年无事件生存率53.9%,单纯IKZF1缺失为83.8%,野生型IKZF1为91.3%(p<0.0001)。
  • 第15天MRD≥0.01%的患者中,暂定高危且IKZF1plus者无事件生存率42.0%、无复发生存率48.0%、总生存率72.7%,与其他组相比p<0.0001。
  • 整合IKZF1plus与第15天MRD阳性识别出复发风险50%的费城染色体阴性B-ALL亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study investigates the potential utility of IKZF1 deletion as an additional high-risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD-guided TPOG-ALL-2013 protocol using 412 newly diagnosed B-ALL patients aged 1-18. IKZF1 status was determined using multiplex ligation-dependent probe amplification. IKZF1 deletions, when co-occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus. Both IKZF1 deletion (14.6%) and IKZF1plus (7.8%) independently predicted poorer outcomes in B-ALL. IKZF1plus was observed in 4.1% of Philadelphia-negative ALL, with a significantly lower 5-year event-free survival (53.9%) compared to IKZF1 deletion alone (83.8%) and wild-type IKZF1 (91.3%) (p < 0.0001). Among patients with Day 15 MRD ≥0.01%, provisional high-risk patients with IKZF1plus exhibited the worst outcomes in event-free survival (42.0%), relapse-free survival (48.0%) and overall survival (72.7%) compared to other groups (p < 0.0001). Integration of IKZF1plus and positive Day 15 MRD identified a subgroup of Philadelphia-negative B-ALL with a 50% risk of relapse. This study highlights the importance of assessing IKZF1plus alongside Day 15 MRD positivity to identify patients at increased risk of adverse outcomes, potentially minimizing overtreatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liu HC, Huang YJ, Jaing TH, et al. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity. Br J Haematol. 2024. PMID: 38479427. doi:10.1111/bjh.19338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。